Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mahieu

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
La Revue De Medecine Interne|January 1, 1988
[Circulating anticoagulants excluding hemophilia. Multicenter survey undertaken under the aegis of the French National Society of Internal Medicine apropos of 207 cases]D u Lê Thi Huong, L Guillevin, J Y Borg, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonistA A H P Megens, D Ashton, J C A Vermeire, et al.
Regulatory Toxicology and Pharmacology : RTP|July 23, 2013
Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?E F A Brandon, A S Bulder, J G M van Engelen, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
La Revue De Medecine Interne|January 1, 1988
[Circulating anticoagulants excluding hemophilia. Multicenter survey undertaken under the aegis of the French National Society of Internal Medicine apropos of 207 cases]D u Lê Thi Huong, L Guillevin, J Y Borg, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonistA A H P Megens, D Ashton, J C A Vermeire, et al.
Regulatory Toxicology and Pharmacology : RTP|July 23, 2013
Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?E F A Brandon, A S Bulder, J G M van Engelen, et al.
Pageof 8